EGFR Biomarkers
News and reporting on EGFR biomarkers.
The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
AstraZeneca's Tagrisso Gets Nod From EMA's CHMP in Unresectable EGFR-Mutated NSCLC
If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.
AstraZeneca, Daiichi Sankyo Launch Three New Lung Cancer Trials of Dato-DXd
The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.
Hutchmed, AstraZeneca to Discuss Orpathys, Tagrisso Trial Results With Global Health Authorities
Patients with EGFR- and MET-altered NSCLC benefited from treatment with the drug combo after progressing on Tagrisso alone.
Black Diamond Therapeutics Restructures Workforce, Deprioritizes RAF Program
The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.
Sep 27, 2024
May 16, 2024